ABSTRACT
Introduction
Major cardiovascular and cerebrovascular events (e.g. myocardial infarction and stroke) can occur in individuals without known pre-existing cardiovascular (CV) disease. Because CV diseases are more likely to occur in patients with certain risk factors, prevention of such events, including the accurate identification of those at increased risk, has been developed using traditional CV risk factors (e.g. cigarette smoking, blood pressure, cholesterol, diabetes mellitus, obesity, family history of CV diseases). The coexistence of multiple CV risk factors multiplies the risk of adverse CV events. (1) Following this, total CV risk assessment using models that include multiple CV risk factors is recommended. One of these models is the Framingham Risk Score (FRS), a simplified prediction tool developed to enable clinicians to estimate CV risk in individuals, often considered the reference standard. (2) It includes age, gender, smoking, blood pressure, total and HDL-cholesterol values, and diabetes, and estimates the 10 year risk of CV events by stratifying individuals into the three risk categories: low, intermediate, and high. (2) In order to better assess CV risk and to clarify the pathogenesis of atherothrombosis, some biochemical markers are stressed. One of them is mean pla-telet volume (MPV), a potential marker of platelet reactivity, which is one of the major culprit mechanisms in atherothrombotic events. Large platelets -characterized by a higher MPV -contain more dense granules and are metabolically and enzymatically more active than small platelets; therefore these platelets have higher thrombotic potential. Elevated values of MPV are associated with CV diseases, and also predict a poor outcome following acute coronary events or coronary interventions. (3) Several reports have demonstrated an association between MPV and traditional CV risk factors, such as hypertension, impaired fasting glucose, diabetes, hypercholesterolemia and obesity, suggesting a possible mechanism in increasing CV risk. (4-8) Based on these proven associations between MPV and single CV risk factors, in light of recommendations for total CV risk assessment, (1) we assessed the association between MPV and total CV risk.
Materials and Methods

Subjects
In this study we enrolled 216 consecutive subjects [146 (65.74%) males], all older than 18 years of age (median age 65 (26-87) years), without a history of clinically apparent CV diseases, that had been admitted to the Cardiology Department at the University Hospital of Split due to multiple CV risk factors. Recent research has shown that rosuvastatin and losartan can interfere with MPV so patients who used them were exluded from our study to eliminate possible errors. Exclusion criteria consisted of a previous diagnosis of CV diseases (coronary artery disease, history of myocardial infarction or stroke, chronic heart failure), thyroid disease, renal or hepatic dysfunction, hematological disease, cancer, thrombocytopenia, autoimmune disease, systemic inflammatory conditions, pregnancy, use of estrogen therapy (oral contraceptives or hormone replacement therapy) or serotonin reuptake inhibitor drug use. The study was conducted according to the principles of the Helsinki Declaration. The local Ethics Committee gave approval for this study. All patients agreed to participate voluntarily in the study after a detailed explanation of study objectives. All participants provided written informed consent after detailed explanation of study objectives. Collection of patient data Trained research assistants filled out the questionnaire on demographic characteristics (age, sex, height and weight), the presence of traditional CV risk factors (arterial hypertension, diabetes, hypercholesterolemia, hypertriglyceridemia, cigarette smoking, family history of CV diseases), and medication used before admission. The presence of CV risk factors was defined as following: (1) diabetes mellitus -fasting blood glucose > 6.9 mmol/L or non-fasting glucose level > 11 mmol/L, or use of antidiabetic medication. The subjects were identified as either presently suffering from diabetes or not; (2) arterial hypertension -systolic blood pressure >140 mm Hg, diastolic blood pressure >90 mm Hg, or previous use of antihypertensive drugs; (3) hypercholesterolemia -total cholesterol (TC) >4.5 mmol/L, LDLcholesterol (LDL-C) >2.5 mmol/L, or previous use of lipid-lowering therapy; (4) hypertriglyceridemia -triglycerides (TG) >1.8 mmol/L; (5) overweightbody mass index (BMI: weight/height 2 ) > 25 kg/m 2 ; (6) cigarette smoking was categorized as non smoking or ever smoking; (7) family history of CV diseases included a history of sudden death, myocardial infarction, angina pectoris or coronary revascularization in a first relative before the age of 55 years (men) or 65 years (women). Collection and processing of diagnostic blood specimen Blood samples were collected in the morning after a 20-min rest following a fasting period of 12 hours for the measurement of TC, LDL-C, HDL-cholesterol (HDL-C), TG, and serum glucose. Plasma concentrations of glucose, TG, TC and HDL-C (after selective precipitation with Immuno AG, Vienna, Austria)
were measured by standard enzymatic methods on an Olympus AU-640 (Olympus, Tokyo, Japan). LDL-C was calculated using the Friedwald equation. If TG concentration was above 3 mmol/L, HDL-C and LDL-C were measured by direct immunoinhibition method (Olympus Diagnostica, Lismeehan, Ireland) and homogeneous assay (Randox Laboratories, Crumlin, United Kingdom), respectively. MPV was measured within 30 minutes of sampling by Bechman Counter (USA) in a blood sample collected in citrate (1:4 v/v) in order to avoid platelet swelling induced by EDTA. Normal range of MPV in our laboratory ranged from 6-10.8 fL. Assessment of individual's CV disease risk level Eight risk factors (age, sex, systolic and diastolic blood pressure, cholesterol and HDL-C levels, smoking, diabetes) were used to calculate an individual's risk level of future development of CV diseases based on the FRS. Among these factors, age, blood pressure, cholesterol and HDL-C levels were processed according to their values and sex, smoking and diabetes were processed depending on whether it was positive or negative. Using these risk factors, the 10-year predicted risk of developing manifest CV disease was calculated for each case. In accordance with the FRS, the study population was then categorized as low (<10%), intermediate (11-19%) , and high (>20%) risk. After that, in order to better estimate total CV risk, FRS was adjusted for TG, BMI and family history of CV diseases, traditional CV risk factors that are not included in the FRS equation. High sensitivity C-reactive protein (hs-CRP) as a control Hs-CRP, widely accepted as an independent predictor of CV diseases, significantly correlates with calculated 10-year FRS. (9) Therefore, we tested the correlation between hs-CRP and FRS as a confirmation that our study hypothesis was properly set. Hs-CRP determination was performed with high sensitivity immunoturbidimetric assay (Cobas Integra 700, Roche, Mannheim, Germany) with a detection limit of 0.25 mg/L, at the time of admission and in a blind fashion.
Statistical analysis Calculation of differences between baseline characteristics is presented as a means and standard deviation (M±SD) or percentage frequencies.
Normally distributed values were compared with Student's tests, and skewed continuous variables by non-parametric rank sum tests. Chi-square tests or Fisher's exact test were used for categorical variables. Pearson's correlation was used to evaluate the association between MPV and serum values for single CV risk factors (age, sex, serum glucose, TC, HDL-C, LDL-C, systolic and diastolic blood pressure, BMI, smoking). The same test was used in assessment of the correlation between MPV and total CV risk expressed as FRS before and after adjusting for multiple potential confounders such as TG, BMI and a family history of CV disease. 
Results
The baseline characteristics of the study population by FRS are presented in according to terciles of MPV after adjusting for TG, BMI, and family history for CV diseases, is presented in figure  1, 
Discussion
Although the association between MPV and single traditional CV risk factors has previously been tested, to the best of our knowledge this study is the first to investigate the association between MPV and total individual CV risk. Contrary to most previous studies, (3) (4) (5) (6) (7) (8) factors in atherogenesis and also in CV risk prediction. Namely, the FRS does not account for metabolic syndrome which is strongly associated with atherogenesis, and often underestimates total CV risk in patients with these risk factors. (16) (17) (18) Correlation between MPV and high total CV risk, observed in our study, suggests the possibility that increased MPV reflects advanced vascular damage. Even in asymptomatic patients with multiple CV risk factors. Namely, damaged vascular cells release substances that activate platelets, and increase thrombogenesis and the potential for development of adverse CV events. (12, 13) In this light, it is possible to interpret the results of studies that have shown associations between increased MPV with target organ damage in patients with hypertension and diabetes, (14, 15) and also in patients with acute coronary syndrome. (19, 20) As in acute coronary syndrome, in which rupture of the fibrous cap allows contact of the platelets with the highly thrombogenic necrotic core, (19, 20) vascular damage, caused by multiple CV risk factors, enables contact between platelets and thrombogenic substances even in asymptomatic patients. In both cases, the result is platelet activation. Therefore, increased platelet activity primarily appears as a consequence, not a cause of vascular damage. Previous studies also stress autonomic imbalances -increased sympathetic or decreased parasympathetic nervous system activity -as an important factor in the progression of atherosclerotic diseases, and development of their complications. (21) Moreover, it has been reported that lower heart rate variability (HRV) -which represents a domination of sympathetic activity -is significantly associated with individual CV risk factors (22, 23) We revealed a significant positive linear correlation between FRS values with hs-CRP, which is widely accepted as an independent predictor of CV diseases. (9, 11) In agreement with our data, a positive correlation between hs-CRP with calculated 10-year FRS has been previously confirmed. (9,11) Therefore, a positive association between hs-CRP with unadjusted and adjusted calculated 10-year FRS, confirms the meaningfulness of our hypothesis and properly conducted research. Also, this observation suggests hs-CRP is a significantly better marker of CV risk than MPV, and supports the observation that inflammation has an active role in the initiation and progression of atherosclerotic disease. (10) Study limitations. We acknowledge the following limitations in this study. This was a cross-sectional rather than a prospective study. Also, the blood sample from each participant in the study was taken only once. Therefore, we were unable to investigate how temporary changes in levels of serum parameters might impact the FRS and its relation to MPV; also, for the same reasons, we were unable to identify a causal relationship between MPV and FRS. It is possible that rosuvastatin and losartan exhibit antithrombotic properties independently to changes in the lipid profile or blood pressure. (26, 27) Therefore, it is important that not a single patient included in our study used these drugs. There are no data about the potential effect of the other antihypertensive and hypolipidemic drugs on MPV values. Moreover, all of these drugs have been used in previous studies in which positive associations between MPV and single CV risk factors were observed. Also, we eliminated potential technical factors which could have affected our results. EDTA, used for anticoagulation of whole blood prior to automated cell counting, may increase MPV due to platelet swelling. (28, 29) However, it has been confirmed that MPV can be measured accurately by using EDTA and citrate if the analysis is performed within 1 h of sampling. (28,29) Also, it has been shown that changes in MPV, which reflect platelet sphering and swelling, were greatest between 30 and 60 min in blood stored at ambient temperature. Because, in our study, blood samples were stored at 4°C and measurements were performed within 30 min after collecting, using the same device, we are confident in the validity of our laboratory measurements. Finally, study subjects consisted of patients with a high CV risk referred to us for cardiology assessment for multiple CV risk factors; therefore selection was potentially biased. However, a significant positive (unadjusted and adjusted) association between hs-CRP with calculated 10-year FRS is confirmation that our results were properly taken and processed.
Conclusion
Linear correlations between hs-CRP with FRS values confirm inflammation as an important mechanism in the initiation and progression of atherogenesis. Correlation of MPV with high total CV risk suggests increased platelet activity primarily as a reflection of advanced atherosclerosis, and possible vascular damage, even in asymptomatic patients.
